<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="120976">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01848171</url>
  </required_header>
  <id_info>
    <org_study_id>20130328</org_study_id>
    <nct_id>NCT01848171</nct_id>
  </id_info>
  <brief_title>Effects of L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Hypothyroidism</brief_title>
  <official_title>Effects of Long-term L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Patients With Hypothyroid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Provincial Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothyroidism is a common clinical entity which is often complicated by dyslipidemia. It is
      also reported increased risk for incidence of atherosclerosis and resulting coronary heart
      disease(CHD), heart failure(HF) and cardiovascular(CV) death. The effect of L-thyroxine
      replacement treatment on serum lipid and atherosclerosis is controversial in hypothyroid
      patients, especially in those with mild or moderate subclinical hypothyroidism. The present
      study was designed to investigate whether L-thyroxine replacement was effective in improving
      serum lipid profiles and retarding atherosclerosis progress.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate of First CVD Events, CVD Mortality and All-cause Mortality</measure>
    <time_frame>endpoint of the trail</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Lipid Levels</measure>
    <time_frame>baseline, 3 months, 6 months, every 12 months during the follpwing follow-up period until the trial is completed</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Thickness of Blood Vessel Wall</measure>
    <time_frame>baseline, 3 months, 6 months, every 12 months during the following follow-up period until the trial is completed</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oxidative Stress and Chronic Inflammatory Factors Associated with Atherosclerosis</measure>
    <time_frame>baseline,  3 months, 6 months, every 12 months during the following follow-up period until the trail is completed</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Hypothyroidism</condition>
  <condition>Thyroid Diseases</condition>
  <condition>Endocrine System Diseases</condition>
  <arm_group>
    <arm_group_label>L-thyroxine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration, tablets, starting dose 25 or 50 micrograms once daily, during the follow-up period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>blank</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-thyroxine</intervention_name>
    <arm_group_label>L-thyroxine</arm_group_label>
    <other_name>Euthyrox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  40~75 years old

          -  Diagnosis of overt or subclinical hypothyroidism in two occasions with a minimum
             interval period of three months

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Severe hepatic or renal dysfunction

          -  Psychiatric disabilities, acute cardiovascular and cerebrovascular diseases, chronic
             respiratory diseases, familiar hypercholesterolemia, malignancy, cholelithiasis,
             pancreatitis, bowel diseases and other disorders influencing lipid and bile acid
             metabolism

          -  Taking lipid-lowering agents and other drugs influencing thyroid function, lipid and
             bile acid metabolism

          -  Obviously poor compliance.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhao jiajun</last_name>
    <role>Study Chair</role>
    <affiliation>Shandong Province Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gao Ling</last_name>
    <phone>+8613793187189</phone>
    <email>gaoling1@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meng Zhao</last_name>
      <phone>86531-68776094</phone>
      <email>zjsylpzm@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 19, 2013</lastchanged_date>
  <firstreceived_date>May 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Provincial Hospital</investigator_affiliation>
    <investigator_full_name>Jia-jun Zhao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hypothyroidism</keyword>
  <keyword>Lipid</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>Chronic Inflammation</keyword>
  <keyword>Endothelial Function</keyword>
  <keyword>Adipocytokine</keyword>
  <keyword>L-thyroxine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Hypothyroidism</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
